About This Video
CSE's Barrington Miller is joined by Anthony Durkacz, Interim CEO of FSD Pharma (CSE:HUGE) to discuss the company's recent history and transition from the cannabis-era to new opportunities in the growing psychedelics space.
Here's an overview of what Barrington and Anthony discuss in this edition of the "Exchange for Entrepreneurs" podcast:
0:00 - Introducing Anthony Durkacz, Interim CEO of FSD Pharma
5:45 - Working back towards a 1Bn market cap
8:10 - The latest investment in Lucid Psycheceuticals Inc. and treating MS
10:50 - The psychedelics movement
14:13 - Listing on NASDAQ
Subscribe for more great CSE insights and interviews here: https://go.thecse.com/CSETV-Subscribe
STAY CONNECTED WITH THE CSE
=============================
- PODCAST: https://blog.thecse.com/cse-podcasts/
- INSTAGRAM: https://www.instagram.com/canadianexchange/
- LINKEDIN: https://ca.linkedin.com/company/canadian-securities-exchange
- FACEBOOK: https://www.facebook.com/CanadianSecuritiesExchange/
- TWITTER: https://twitter.com/CSE_News
- BLOG: https://blog.thecse.com/
- WEBSITE: https://thecse.com/
Subscribe for more great CSE insights and interviews here: https://go.thecse.com/CSETV-Subscribe
STAY CONNECTED WITH THE CSE
=============================
- PODCAST: https://blog.thecse.com/cse-podcasts/
- INSTAGRAM: https://www.instagram.com/canadianexchange/
- LINKEDIN: https://ca.linkedin.com/company/canadian-securities-exchange
- FACEBOOK: https://www.facebook.com/CanadianSecuritiesExchange/
- TWITTER: https://twitter.com/CSE_News
- BLOG: https://blog.thecse.com/
- WEBSITE: https://thecse.com/
- MAGAZINE: https://issuu.com/thecse/docs
MB01CLWYMSAUQW3
Read the TranscriptAuto-generated by YouTube; names and terms may be misspelled.
hi welcome to the canadian securities exchange podcast series actually this is season two i'm your host barrington miller director of issuer engagement at the csc and today i am here with interim ceo mr anthony durkatz of fsd pharma welcome to the show anthony thank you mr durkats tell us a little bit about yourself and tell us where fsd pharma was and then we'll get to where it's going
thank you yeah so so we're we're my background is is you started on the capital markets trading floor then then got into m a ultimately ended up becoming the majority owner of first republic capital where we focused on microcap deals we've done a lot of deals in so many different industries and then really sort of transformed into a merchant bank where we would invest
money alongside deals that that we found interesting and and and so fsd was one of those those those companies we we saw it was an opportunity to help them raise money to take them public so we did it we did it in a big way it was during the cannabis heydays of of 2017 2018 where you did have a very very different market and when we began trading on the csc
you know i mean we we did break every volume trading record you know the exchange had ever had and and so i i guess we became a very well known symbol in in canada but but you know looking back at it it's almost hard to say if it was a good thing or a bad thing because so many people got involved and so many investors got
involved and when the cannabis industry itself unwound and and the company itself missed on a number of of performance targets and metrics and and there were agreements that had that had not worked out it was it was it was challenging and and so there were a lot of of shareholders in canada here that saw a significant downturn and so now you know going through what fsd has gone
through i sit as as an interim ceo a co-founder one of the largest shareholders of the company to to try to turn that around and what what i'm excited and i'm not excited about the past and and and very humbled by some of the patients shareholders have shown us but what we really want to do is we've we've sort of re-pivoted the company
and and sort of you know looked at you know what was positive what's been really good where were we successful and and today the company is an exceptional cash position and so now the the the mandate of the board is now how do we help equate that to to benefit shareholders and so that's sort of my history and why i'm talking to you now as interim ceo of fsd
no i'm not necessarily by your choice by the way you know i i'm interim and we are actively looking for a ceo who has biotechnology experience that has done previous deals that have partnered with big pharma or sold to big pharma and has capital markets experience because we also have the dual listing here in the csc and on the nasdaq to try to try to leverage those types of strengths and
access to capital and in a much much bigger global investment community so i'm going to put a pin in the in the nasdaq one just because it's fascinating and the process of actually going through it i'm sure was very very thorough and and i i think we were the first or second dually listed csc company to to yeah at the time yeah yeah i do want to say
the first but we'll have to we'll have to fact check that definitely top two so traveling a little bit back in time to a few weeks ago where i was out at a another company event and i ran into mr durkats and of course we did the socially distance and acceptable greetings and said hello and all of those good things and it's nice
to see people again live we were talking about that was the first that was the first event f financing related event in the financial district i'd been to since you know since march of 2020 yes yes which is yeah me too imagine no but yeah we definitely remembered how to how to how to how to behave at these these types of events much better than
before much better than before so we got talking and i'm like hey anthony so what's what's going on and it was there that anthony durkats made a very very bold proclamation as to what his wish what his desire what his dream what his goal is for fsd pharma and the new direction that it's going and the passion behind it so i'm not going to steal the punchline but
i'm going to do that setup and i'm turning it over to you where is fsd going nowadays yes so you know in in in looking back in in and trying to to rebuild shareholder value you know one of one of the metrics that we had achieved in 2018 was over a billion market cap and so you know not not saying anything and we're not making any claims or anything like that in in
my wish list and in my target you know the idea is you know how do we get back to to those to that type of capitalization and so to me technology is is critical technology is one of those few areas that will allow you to get to to to that base and really what's really exciting and and has real potential to do that so when we take fsd today
became a biotechnology company had a drug candidate called fsdpa which was in sync with cannabis not because it's a cannabis or cannabinoid but that the actual molecule enters the human body the exact same way cannabis does through your cb2 receptor into your endocannabinoid system and and what we saw and and we're excited about is that like many people have said about cannabis in the past that they have
anti-inflammation properties and they have anti-pain properties that are not addictive it it we we find that true whether or not it's cannabis if it enters your cb2 receptor through the endocannabinoid system so with with that idea in mind we wanted to go out and and and and and follow an actual drug pipeline through fda approvals the good news is that fsdpa had successfully completed phase one trials showed excellent
safety we completed the toxology those will get announced as soon as they're ready and now we've we we've built an incredible team with our latest most recent acquisition of two weeks ago to to to to look at what the best indication or target should be for fsd pea but with this acquisition that we just completed which is lucid lucid brings two additional drug candidates one which is in the psychedelic space
and it's a molecule what i can say about it and which interested me about it because i do see a lot of different i saw a lot of different psychedelic deals companies and opportunities is that this was totally unique and different the target is for depression but it's not lsd it's not mdma it's not ketamine it's not ibogaine it's not dmt it's not psilocybin it's not what people
think about when they think about psychedelics and that's what really got me interested and excited about that and the this the second drug candidate that our this recent acquisition brings to the table is a drug candidate to target ms so in both multiple sclerosis and in depression there is no cure today and what we saw and what we were able to see in animal modeling was really really exciting
today if you have ms or if you're diagnosed with ms by your doctor that's that's this very heavy burden of information to to be given which can lead to depression and that's where these tie in so because there's no treatment for depression and you can become depressed or clinically depressed when you are diagnosed with with a serious disease a target for depression which is a totally different
psychoactive psychedelic molecule than than people are accustomed to and a a drug candidate that shows the promise to not only protect but the target is to reverse ms so if if people have lost their the ability to walk or they need a walker or they have to or they're in a wheelchair you know this is something where we see potential and and you know there's a long road to potential
to try to actually reverse that and that's what no drug or treatment today does in ms and current treatments for depression as we know hundreds of millions of people globally suffer from it and and we're still we're still not you know we're we're we're better and and technology has helped us but we're we're not we're not there yet and that's where we see that psychedelic new frontier of medicine that gets us
really really excited you know it's some people are concerned that you know psychedelics is is a fad that it's a new new wave that it's not really here to stay i mean i have my own personal opinion i don't think it's a it's not a quick game it's not this is not cannabis and i can't reiterate that enough as far as an industry as far as the way companies develop
but the the health benefits the health and wellness quality of life like you're talking about really massive human changes and that's exciting and the opportunities that are there for companies like this to be to be funded to grow to expand and and to do research is is is incredible and that's really our job you know as a microcap company we we have to try to do what we can to to make an impact and
i think that's true of any company especially microcaps you know you're one of millions you know how do how do you stand out and and if you can't stand out as a micro cap technology company it's very difficult to survive you know when you think of like investment there are similarities to what happened in cannabis and cannabis stocks and and you know looking at at in general no matter what you know
anytime someone's investing in any single stock especially a micro cap no matter what the industry is you know just be very very careful do all of your own research and diligence and and never it's a gamble that's ultimately what it is and and never ever ever invest more than you can afford to lose that you can afford to lose in its entirety and so that it wouldn't impact your
financial quality of life and i think that's you know more than ever really important i think we see a lot of traders and investors bite more than they can chew and and it's it's not it's not good it's not right and and you shouldn't you know you should you should be very very careful when looking at at making investments in in any micro cap and any individual
stock for example in 2008 you know i saw royal bank of scotland which was one of the 10 biggest banks in the world you know collapsed to zero and you saw lehman brothers and bear stearns and you know stuff that you thought was never possible and too big to fail too big to and and but you know in the world of micro caps and investing in micro caps
you have to be willing to lose everything you're investing incapable of losing it and not getting not not getting or not making the wrong decision in that respect no we we appreciate your candor and you know if you're watching this and you're you're thinking about investing we are not giving investment advice on this program we are giving some life advice now you were talking a little bit earlier
about nasdaq and how you are now dually listed on nasdaq what was the experience like to get onto nasdaq and what has it been like since you've been what are the benefits as well both to you and your investors so i i would say the the main and this would be for any company liquidity you have access to more liquidity on nasdaq you know when we're comparing
canada to anything even you're talking about the tsx proper if you're talking about london if you're talking about hong kong you know being a technology company on a u.s big board so predominantly nasdaq there is enormous amounts of liquidity and so at the right time you can leverage that liquidity you know to to raise money you you're open to a broader range of investors like for
example some brokers you know can't trade certain stocks on certain exchanges under certain dollar values under certain market caps and and so that you know is is definitely a benefit and and it really there's access to capital in canada you know raising money for living in micro caps in canada i can say that you know to raise two million dollars in canada in a sector that's that's highly
bullish in in the usa you can probably raise 20 or 30 or 40 million with the same same amount of work would be the best way to describe that well it makes sense ten times excuse me ten times the population size of course yeah makes makes sense so listen anthony i know you're extremely busy and i just wanna say thank you on behalf of the canadian
securities exchange for your time for the update for fsd pharma ticker symbol is h-u-g-e huge huge i've been your host barrington miller this has been a brief update as to what's going on with fsd pharma and of course you've heard it here on the canadian securities exchange podcast for more for more content like this visit us again on youtube csetv we're on instagram linkedin twitter and facebook
and we'll see you at the next episode thank you
you



